MedWell Ai Reports Revenue Surge and Reduced Loss in Q1 2026

MedWell Ai (OTCQB: MWAI) has reported a strong financial performance for the quarter ended March 31, 2026, with total revenue reaching $618,676 compared to $281,318 in the same period last year, marking a significant increase. The company also reduced its net loss to $227,939 from $814,192, while reaffirming full-year revenue guidance of $2.3 million. The nine-month revenue surged to $1.69 million from $425,327, underscoring the success of its AI-driven B2B pharma procurement operations led by MedWell USA. The company continues to lower expenses and liabilities, positioning itself for sustainable growth.

Management attributes this progress to the expansion of its AI-driven B2B pharma procurement operations and outlined plans for strategic acquisitions to build a vertically integrated wellness platform. This platform will span biologics manufacturing, procurement services, software solutions, and back-office infrastructure. The strategy aims to capitalize on inefficiencies in healthcare procurement, drive margin expansion, and support scalable growth. MedWell Ai operates through three key subsidiaries: MedWell USA for B2B distribution, MedWell Direct (TeleMD.Ai) for telemedicine platforms, and MedWell Facilities for real estate and AI-driven software for wellness clinics.

The company's vision is to create a comprehensive ecosystem that addresses the fragmented healthcare procurement market. By leveraging AI and technology, MedWell Ai intends to streamline operations for medical offices, wellness clinics, gyms, and telemedicine companies. The progress reported in the quarterly filing reflects the company's commitment to innovation and operational efficiency. For more details, the full press release is available at https://ibn.fm/gLWAp.